ACM
CRNX icon

ADAR1 Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

ADAR1 Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.4M Buy
1,139,331
+829,963
+268% +$37.1M 2.44% 8
2025
Q4 		$14.4M Buy
309,368
+61,000
+25% +$2.72M 1.06% 20
2025
Q3 		$10.3M Buy
248,368
+195,243
+368% +$6.24M 0.97% 23
2025
Q2 		$1.53M Hold
53,125
– – 0.23% 66
2025
Q1 		$1.78M Hold
53,125
– – 0.33% 62
2024
Q4 		$2.72M Sell
53,125
-35,300
-40% -$1.97M 0.54% 40
2024
Q3 		$4.52M Buy
88,425
+13,575
+18% +$700K 0.73% 28
2024
Q2 		$3.35M Buy
+74,850
New +$3.46M 0.63% 27

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return